Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells

Immunology

Volumn 128, Issue 1 PART 2, 2009, Pages

  Huang, Wei Ching ^a   Lin, Yee Shin ^a   Wang, Chi Yun ^a   Tsai, Cheng Chieh ^a   Tseng, Hsiang Chi ^a   Chen, Chia Ling ^a   Lu, Pei Jung ^a   Chen, Po See ^a   Qian, Li ^b,c   Hong, Jau Shyong ^c   Lin, Chiou Feng ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Glycogen synthase kinase 3; Interleukin 10; Lipopolysaccharide; Microglia; Nitric oxide

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; CYCLIC AMP; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PROTEIN KINASE B; RANTES; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE; CHEMOKINE CCL5; DOWN-REGULATION; GLYCOGEN SYNTHASE KINASE 3; INFLAMMATION; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 68249159584     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2008.02959.x     Document Type: Article

References (63)

1. Balk RA. Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations. Crit Care Clin 2000 16 : 179 92.
2. Sessler CN, Perry JC, Varney KL. Management of severe sepsis and septic shock. Curr Opin Crit Care 2004 10 : 354 63.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001 29 : 1303 10.
4. Williams MD, Braun LA, Cooper LM, Johnston J, Weiss RV, Qualy RL, Linde-Zwirble W. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care 2004 8 : R291 8.
5. Rivers E. The outcome of patients presenting to the emergency department with severe sepsis or septic shock. Crit Care 2006 10 : 154.
6. Patel GP, Gurka DP, Balk RA. New treatment strategies for severe sepsis and septic shock. Curr Opin Crit Care 2003 9 : 390 6.
7. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001 29 : S99 106.
8. Cohen J. The immunopathogenesis of sepsis. Nature 2002 420 : 885 91.
9. Netea MG, van der Meer JW, van Deuren M, Kullberg BJ. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol 2003 24 : 254 8.
10. van Deventer SJH, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990 76 : 2520 6.
11. Papathanassoglou EDE, Moynihan JA, Ackerman MH. Does programmed cell death (apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? A review and a theoretical framework. Crit Care Med 2000 28 : 537 49.
12. Mahidhara R, Billiar TR. Apoptosis in sepsis. Crit Care Med 2000 28 : N105 13.
13. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006 6 : 813 22.
14. Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A. The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets 2007 8 : 493 500.
15. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007 8 : 57 69.
16. Goodman RB, Pugin J, Lee JS, Matthay MA. Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev 2003 14 : 523 35.
17. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004 351 : 159 69.
18. Triantafilou M, Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 2002 23 : 301 4.
19. Qin L, Li G, Qian X, Liu Y, Wu X, Liu B, Hong JS, Block ML. Interactive role of the toll-like receptor 4 and reactive oxygen species in LPS-induced microglia activation. Glia 2005 52 : 78 84.
20. Zhou H, Lapointe BM, Clark SR, Zbytnuik L, Kubes P. A requirement for microglial TLR4 in leukocyte recruitment into brain in response to lipopolysaccharide. J Immunol 2006 177 : 8103 10.
21. ter Steege JC, van de Ven WC, Forget PP, Buurman WA. Regulation of lipopolysaccharide-induced NO synthase expression in the major organs in a mouse model. The roles of endogenous interferon-gamma, tumor necrosis factor-alpha and interleukin-10. Eur Cytokine Netw 2000 11 : 39 46.
22. Salkowski CA, Detore G, McNally R, van Rooijen N, Vogel SN. Regulation of inducible nitric oxide synthase messenger RNA expression and nitric oxide production by lipopolysaccharide in vivo: the roles of macrophages, endogenous IFN-gamma, and TNF receptor-1-mediated signaling. J Immunol 1997 158 : 905 12.
23. Hu S, Chao CC, Ehrlich LC, Sheng WS, Sutton RL, Rockswold GL, Peterson PK. Inhibition of microglial cell RANTES production by IL-10 and TGF-beta. J Leukoc Biol 1999 65 : 815 21.
24. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001 19 : 683 765.
25. Gerard C, Bruyns C, Marchant A et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993 177 : 547 50.
26. Drazan KE, Wu L, Bullington D, Shaked A. Viral IL-10 gene therapy inhibits TNF-alpha and IL-1 beta, not IL-6, in the newborn endotoxemic mouse. J Pediatr Surg 1996 31 : 411 4.
27. Leon LR, Kozak W, Kluger MJ. Role of IL-10 in inflammation. Studies using cytokine knockout mice. Ann N Y Acad Sci 1998 856 : 69 75.
28. Eaton S, Martin G. Clinical developments for treating ARDS. Expert Opin Investig Drugs 2002 11 : 37 48.
29. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy - review of a new approach. Pharmacol Rev 2003 55 : 241 69.
30. Braat H, Rottiers P, Hommes DW et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006 4 : 754 9.
31. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005 6 : 777 84.
32. Woodgett JR, Ohashi PS. GSK3: an in-Toll-erant protein kinase? Nat Immunol 2005 6 : 751 2.
33. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 2004 279 : 39541 54.
34. Dugo L, Collin M, Allen DA et al. GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 2005 33 : 1903 12.
35. Dugo L, Collin M, Allen DA, Murch O, Foster SJ, Yaqoob MM, Thiemermann C. Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: role of glycogen synthase kinase-3beta inhibition. Crit Care Med 2006 34 : 1489 96.
36. Whittle BJ, Varga C, Posa A, Molnar A, Collin M, Thiemermann C. Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br J Pharmacol 2006 147 : 575 82.
37. Cuzzocrea S, Mazzon E, Di Paola R et al. Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin Immunol 2006 120 : 57 67.
38. Cuzzocrea S, Di Paola R, Mazzon E et al. Glycogen synthase kinase 3beta inhibition reduces the development of nonseptic shock induced by zymosan in mice. Shock 2007 27 : 97 107.
39. Bao Z, Lim S, Liao W, Lin Y, Thiemermann C, Leung BP, Wong WS. Glycogen synthase kinase-3beta inhibition attenuates asthma in mice. Am J Respir Crit Care Med 2007 176 : 431 8.
40. Dugo L, Collin M, Thiemermann C. Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock 2007 27 : 113 23.
41. Muhl H, Pfeilschifter J. Controlling the cytokine storm by insulin: glycogen synthase kinase-3 as a target in systemic inflammation. Crit Care Med 2006 34 : 1567 9.
42. Dugo L, Collin M, Allen DA et al. Inhibiting glycogen synthase kinase 3beta in sepsis. Novartis Found Symp 2007 280 : 128 42.
43. Qian L, Block ML, Wei SJ et al. Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase. J Pharmacol Exp Ther 2006 319 : 44 52.
44. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001 359 : 1 16.
45. Grimes CA, Jope JS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001 65 : 391 426.
46. Pengal RA, Ganesan LP, Wei G, Fang H, Ostrowski MC, Tridandapani S. Lipopolysaccharide-induced production of interleukin-10 is promoted by the serine/threonine kinase Akt. Mol Immunol 2006 43 : 1557 64.
47. Liu YW, Tseng HP, Chen LC, Chen BK, Chang WC. Functional cooperation of simian virus 40 promoter factor 1 and CCAAT/enhancer-binding protein beta and delta in lipopolysaccharide-induced gene activation of IL-10 in mouse macrophages. J Immunol 2003 171 : 821 8.
48. Liu YW, Chen CC, Tseng HP, Chang WC. Lipopolysaccharide-induced transcriptional activation of interleukin-10 is mediated by MAPK- and NF-kappaB-induced CCAAT/enhancer-binding protein delta in mouse macrophages. Cell Signal 2006 18 : 1492 500.
49. Chiang BT, Liu YW, Chen BK, Wang JM, Chang WC. Direct interaction of C/EBPdelta and Sp1 at the GC-enriched promoter region synergizes the IL-10 gene transcription in mouse macrophage. J Biomed Sci 2006 13 : 621 35.
50. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000 406 : 86 90.
51. Dugo L, Abdelrahman M, Murch O, Mazzon E, Cuzzocrea S, Thiemermann C. Glycogen synthase kinase-3beta inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation. Shock 2006 25 : 485 91.
52. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007 32 : 577 95.
53. Liu B, Gao HM, Hong JS. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 2003 111 : 1065 73.
54. Ringheim GE, Conant K. Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections). J Neuroimmunol 2004 147 : 43 9.
55. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008 9 : 46 56.
56. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008 29 : 357 65.
57. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007 55 : 453 62.
58. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 2005 25 : 8843 53.
59. VanOtteren GM, Strieter RM, Kunkel SL, Paine R III., Greenberger MJ, Danforth JM, Burdick MD, Standiford TJ. Compartmentalized expression of RANTES in a murine model of endotoxemia. J Immunol 1995 154 : 1900 8.
60. Kopydlowski KM, Salkowski CA, Cody MJ, van Rooijen N, Major J, Hamilton TA, Vogel SN. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol 1999 163 : 1537 44.
61. Hu X, Paik PK, Chen J, Yarilina A, Kockeritz L, Lu TT, Woodgett JR, Ivashkiv LB. IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 2006 24 : 563 74.
62. Hu X, Chen J, Wang L, Ivashkiv LB. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol 2007 82 : 237 43.
63. Rodionova E, Conzelmann M, Maraskovsky E et al. GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood 2007 109 : 1584 92.